IL6 and Huntington disease: Figure 7 shows the markers of inflammation and oxidative stress in HD patients. In the placebo group, there was a statistically significant decrease in the plasma concentration of IL-6, which did not occur in the TRF group. This difference continues when comparing HD patients' placebo and intervention groups, as seen in Figure 8.